Plain-English translation of NCT05156983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication designed to quickly reverse the blood-thinning effects of certain oral anticoagulant drugs (like rivaroxaban, apixaban, and edoxaban) in adults who need urgent surgery or invasive procedures. The study compares this new treatment to the current standard approach to see which works better and is safer.
When patients on blood-thinning medications need emergency surgery, doctors need a fast way to reverse those effects to prevent dangerous bleeding during the operation. This trial exists to find out whether this new treatment works better than what doctors currently use.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new treatment () or the standard treatment before your surgery. You'll receive an IV infusion before your operation, and possibly another dose during surgery if the surgeon thinks it's needed. You will need to stay in the hospital, and the research team will call or video chat with you about 30 days after your surgery to check on your recovery.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States